Join the Descovy group to help and get support from people like you.
Descovy News
Half-Million Children Could Die If U.S. AIDS Relief Is Dropped
FRIDAY, April 11, 2025 — Nearly a half-million children could die from AIDS by 2030 if President Donald Trump follows through on plans to cut U.S. relief programs, a new study says. As many as 1 m...
U.S. Foreign Aid Cuts Could Devastate Global Progress Against HIV/AIDS
THURSDAY, March 27, 2025 – HIV could explode worldwide in the wake of U.S. cuts to foreign aid, resulting in millions of AIDS deaths and soaring rates of infection, a new analysis says. President...
Federal Judge Rules FDA, CDC Must Restore Health Websites Removed Under Trump Order
TUESDAY, Feb. 12, 2025 – A federal judge has ordered the U.S. Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) to restore access to public health websites that...
Trump Administration Waives Halt on Distribution of HIV Medications Via PEPFAR
WEDNESDAY, Jan. 29, 2025 – The Trump administration has made some concessions to the halt placed on distributions of global HIV treatments via the U.S. President's Emergency Plan for AIDS Relief...
Preexposure Prophylaxis Use for HIV Increased in Recent Years
MONDAY, Oct. 21, 2024 – Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online Oct. 14 in the Journal of the American Medical ...
FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 3, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a pre-exposure prophylaxis (PrEP) in...
FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir...
FDA Approves Descovy (emtricitabine and tenofovir alafenamide), Gilead’s Third TAF-Based HIV Therapy
FOSTER CITY, Calif., April 04, 2016 --(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Descovy® (emtricitabine 200 ...
Further information
Related condition support groups
Pre-Exposure Prophylaxis, HIV Infection